Nexavar is an oral multiple kinase inhibitor for the treatment of patients with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, and patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer.

Until now, patients with unresectable HCC have had limited treatment options. Now, Nexavar offers a new treatment option with proven clinical benefit for unresectable HCC. This web site provides the latest information about Nexavar for the treatment of patients with unresectable HCC and for the treatment of patients with advanced RCC. It also provides links to comprehensive support programs to help patients with unresectable HCC or advanced RCC manage their therapy.

NexConnect™: Patient Support Program Select Your Condition Information for Advanced Kidney Cancer (RCC) Patients Information for Unresectable Liver Cancer (HCC) Patients Information for Health Care Providers

REACH: Insurance Coverage & Assistance Select Your Condition Information for Advanced Kidney Cancer (RCC) Patients Information for Unresectable Liver Cancer (HCC) Patients Information for Health Care Providers Download Enrollment Form

NEW — HCC Clinical Data for Health Care Providers Now indicated for the treatment of patients with unresectable HCC. Nexavar — the first systemic treatment proven to extend overall survival in patients with unresectable HCC. Click here to connect directly to the Phase 3 Trial Overview

Important Safety Information

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes.

Women of childbearing potential are advised to avoid becoming pregnant and against breastfeeding.